Peptide RL-QN15 promotes wound healing of diabetic foot ulcers through p38 mitogen-activated protein kinase and smad3/miR-4482-3p/vascular endothelial growth factor B axis

Background:Wound management of diabetic foot ulcers(DFUs)is a complex and challenging task,and existing strategies fail to meet clinical needs.Therefore,it is important to develop novel drug candidates and discover new therapeutic targets.However,reports on peptides as molecular probes for resolving issues related to DFUs remain rare.This study utilized peptide RL-QN15 as an exogenous molecular probe to investigate the underlying mechanism of endogenous non-coding RNA in DFU wound healing.The aim was to generate novel insights for the clinical management of DFUs and identify potential drug targets.Methods:We investigated the wound-healing efficiency of peptide RL-QN15 under diabetic con-ditions using in vitro and in vivo experimental models.RNA sequencing,in vitro transfection,quantitative real-time polymerase chain reaction,western blotting,dual luciferase reporter gene detection,in vitro cell scratches,and cell proliferation and migration assays were performed to explore the potential mechanism underlying the promoting effects of RL-QN15 on DFU repair.Results:Peptide RL-QN15 enhanced the migration and proliferation of human immortalized keratinocytes(HaCaT cells)in a high-glucose environment and accelerated wound healing in a DFU rat model.Based on results from RNA sequencing,we defined a new microRNA(miR-4482-3p)related to the promotion of wound healing.The bioactivity of miR-4482-3p was verified by inhibiting and overexpressing miR-4482-3p.Inhibition of miR-4482-3p enhanced the migration and proliferation ability of HaCaT cells as well as the expression of vascular endothelial growth factor B(VEGFB).RLQN15 also promoted the migration and proliferation ability of HaCaT cells,and VEGFB expression was mediated via inhibition of miR-4482-3p expression by the p38 mitogen-activated protein kinase(p38MAPK)and smad3 signaling pathways.Conclusions:RL-QN15 is an effective molecule for the treatment of DFUs,with the underlying mechanism related to the inhibition of miR-4482-3p expression via the p38MAPK and smad3 signaling pathways,ultimately promoting re-epithelialization,angiogenesis and wound healing.This study provides a theoretical basis for the clinical application of RL-QN15 as a molecular probe in promoting DFU wound healing.

智能负压联合自体富血小板凝胶在糖尿病足Wagner 3~4级中的应用效果

目的探讨智能负压联合自体富血小板凝胶在糖尿病足Wagner 3~4级中的应用效果。方法选取2020年2月至2021年5月钦州市第一人民医院住院的80例糖尿病足Wagner 3~4级患者作为研究对象,采用随机数字表法将其分为试验组和对照组,每组各40例。对照组患者采用智能创伤负压综合治疗法,试验组患者采用智能创伤负压联合自体富血小板凝胶治疗。比较两组患者的创面愈合时间、换药次数、溃疡面积、血糖水平、治疗效果及治疗满意度。结果试验组患者治疗4周的换药次数少于对照组,溃疡面积小于对照组,愈合时间短于对照组,血糖水平低于对照组,差异有统计学意义(P<0.05)。试验组患者的治疗总有效率高于对照组,差异有统计学意义(P<0.05)。试验组患者治疗4周的治疗总满意度高于对照组,差异有统计学意义(P<0.05)。结论智能负压联合自体富血小板凝胶治疗糖尿病足Wagner 3~4级,能够有效缓解临床症状,缩小溃疡面积,促进创面快速愈合,住院时间短,满意度高,操作简单,费用低,值得推广应用。

湿润烧伤膏治疗3～5级糖尿病足溃疡的临床体会

目的总结、分析湿润烧伤膏(MEBO)治疗3、4、5级糖尿病足溃疡(DFU)的临床疗效。方法对68例3、4、5级糖尿病足患者的98处皮肤溃疡创面全程采用MEBO规范治疗,并配合相应的基础治疗,观察并记录治疗16周后的创面愈合情况。结果经过16周的治疗,68例患者的98处皮肤溃疡创面的治愈率为73.47%,显效率为20.40%,有效率为6.10%,总有效率为100%。结论 MEBO治疗3、4、5级DFU的疗效显著,方法科学实用,值得临床广泛应用。